Current Report Filing (8-k)
2017年6月7日 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 6, 2017
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer
Identification No.)
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure
On
June 6, 2017, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s Senior Vice President
of Research and Development, Richard Purcell, will be presenting a poster session entitled “OPIOIDS AND SLEEP APNEA: ANTAGONISM
OF REMIFENTANIL INDUCED RESPIRATORY DEPRESSION BY CX1739 IN TWO CLINICAL MODELS OF OPIOID INDUCED RESPIRATORY DEPRESSION”
at the Sleep 2017 conference in Boston, MA on June 6, 2017 from 5:00 to 7:00 p.m. Eastern Time. SLEEP 2017 is the 31st Annual
Meeting of the Associated Professional Sleep Societies LLC, a joint venture of the American Academy of Sleep Medicine and
the Sleep Research Society.
The
content of the poster that Mr. Purcell will be using at the conference is attached as Exhibit 99.1 and is being furnished and
not filed pursuant to Item 7.01 of Form 8-K. The press release announcing the Company’s participation in the conference
is attached as Exhibit 99.2 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RESPIRERX
PHARMACEUTICALS INC.
|
Date:
June 6, 2017
|
|
|
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
Jeff
E. Margolis
|
|
|
Vice
President, Treasurer and Secretary
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Exhibit
Description
|
99.1
|
|
Poster
Content*
|
99.2
|
|
Press
Release dated June 6, 2017*
|
*
Furnished herewith.
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
過去 株価チャート
から 9 2024 まで 10 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
過去 株価チャート
から 10 2023 まで 10 2024
Real-Time news about RespireRx Pharmaceuticals Inc (CE) (その他OTC): 0 recent articles
その他のRespirerx Pharmaceuticals Inc.ニュース記事